FIELD: biotechnology.
SUBSTANCE: lipocalin mutein is obtained which is at least 90% identical to the protein sequence selected from a group consisting of sequences SEQ ID NO: 1-14.
EFFECT: invention allows for producing lipocalin mutein able to bind to hepcidin with an affinity based on the dissociation constant which is equal to approximately 10 nm or less.
73 cl, 12 dwg, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL PROTEINS SPECIFIC FOR ANGIOGENESIS | 2016 |
|
RU2720688C2 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 | 2020 |
|
RU2814653C2 |
| MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3) | 2016 |
|
RU2756318C2 |
| PROTEINS SPECIFIC FOR CD137 | 2016 |
|
RU2736312C2 |
| NOVEL SPECIFIC BINDING POLYPEPTIDES AND ROUTES OF USE THEREOF | 2015 |
|
RU2723034C2 |
| FUSED POLYPEPTIDE WITH ANTI-CANCER ACTIVITY | 2016 |
|
RU2754466C2 |
| HUMAN LIPOCALIN 2 MUTEINS (Lcn2, hNGAL) WITH TARGETED AFFINITY | 2019 |
|
RU2804336C2 |
| HUMAN LIPOLOCAL 2 MALLETES (LCN2, HNGAL) WITH AFFINITY FOR SPECIFIC TARGET | 2010 |
|
RU2707126C2 |
| MUTEINS OF TEAR LIPOCALIN, POSSESSING AFFINITY TO HUMAN C-MET RECEPTOR TYROSINE KINASE AND METHODS OF OBTAINING THEM | 2009 |
|
RU2515063C9 |
